|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M,
et al: EAU Guidelines on Non-Muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandith AA, Shah ZA and Siddiqi MA:
Oncogenic role of fibroblast growth factor receptor 3 in
tumorigenesis of urinary bladder cancer. Urol Oncol. 31:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu XR: Biology of urothelial
tumorigenesis: Insights from genetically engineered mice. Cancer
Metastasis Rev. 28:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim WJ and Bae SC: Molecular biomarkers in
urothelial bladder cancer. Cancer Sci. 99:646–652. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Etheridge A, Lee I, Hood L, Galas D and
Wang K: Extracellular microRNA: A new source of biomarkers. Mutat
Res. 717:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zen K and Zhang CY: Circulating microRNAs:
A novel class of biomarkers to diagnose and monitor human cancers.
Med Res Rev. 32:326–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adam L, Wszolek MF, Liu CG, Jing W, Diao
L, Zien A, Zhang JD, Jackson D and Dinney CP: Plasma microRNA
profiles for bladder cancer detection. Urol Oncol. 31:1701–1708.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng Y, Liu J, Kang Y, He Y, Liang B, Yang
P and Yu Z: miR-19a acts as an oncogenic microRNA and is
up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Y, Kang Y, He Y, Liu J, Liang B, Yang
P and Yu Z: microRNA-99a acts as a tumor suppressor and is
down-regulated in bladder cancer. BMC Urol. 14:502014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fang Z, Dai W, Wang X, Chen W, Shen C, Ye
G and Li L: Circulating miR-205: A promising biomarker for the
detection and prognosis evaluation of bladder cancer. Tumour Biol.
37:8075–8082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motawi TK, Rizk SM, Ibrahim TM and Ibrahim
IA: Circulating microRNAs, miR-92a, miR-100 and miR-143, as
non-invasive biomarkers for bladder cancer diagnosis. Cell Biochem
Funct. 34:142–148. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tölle A, Blobel CC and Jung K: Circulating
miRNAs in blood and urine as diagnostic and prognostic biomarkers
for bladder cancer: An update in 2017. Biomark Med. 12:667–676.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wittekind C, Asamura H and Sobin LH: TNM
Atlas. Hoboken. (New Jersey, US, Wiley-Backwell Publishing). 2014.
View Article : Google Scholar
|
|
18
|
Shah JS, Soon PS and Marsh DJ: Comparison
of methodologies to detect low levels of hemolysis in serum for
accurate assessment of serum microRNAs. PLoS One. 11:e01532002016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blondal T, Jensby NS, Baker A, Andreasen
D, Mouritzen P, Wrang Teilum M and Dahlsveen IK: Assessing sample
and miRNA profile quality in serum and plasma or other biofluids.
Methods. 59 (Suppl):S1–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pritchard CC, Kroh E, Wood B, Arroyo JD,
Dougherty KJ, Miyaji MM, Tait JF and Tewari M: Blood cell origin of
circulating MicroRNAs: A cautionary note for cancer biomarker
studies. Cancer Prev Res (Phila). 5:492–497. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kirschner MB, Edelman JJ, Kao SC, Vallely
MP, van Zandwijk N and Reid G: The impact of hemolysis on cell-free
microRNA biomarkers. Front Genet. 4:942013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fraser CG: Biological variation-from
principles to practice. Washington. (DC, U.S., AACC Press).
2001.
|
|
24
|
Ammerlaan W and Betsou F: Intraindividual
temporal miRNA variability in serum, plasma, and white blood cell
subpopulations. Biopreserv Biobank. 14:390–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ciesla M, Skrzypek K, Kozakowska M, Loboda
A, Jozkowicz A and Dulak J: MicroRNAs as biomarkers of disease
onset. Anal Bioanal Chem. 401:2051–2061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Peng B, Wang D, Ma X, Jiang D,
Zhao J and Yu L: Human tumor microRNA signatures derived from
large-scale oligonucleotide microarray datasets. Int J Cancer.
129:1624–1634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang X, Liang M, Dittmar R and Wang L:
Extracellular microRNAs in urologic malignancies: Chances and
challenges. Int J Mol Sci. 14:14785–14799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
MacLellan SA, MacAulay C, Lam S and Garnis
C: Pre-profiling factors influencing serum microRNA levels. BMC
Clin Pathol. 14:272014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ratert N, Meyer HA, Jung M, Lioudmer P,
Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert
S, et al: miRNA profiling identifies candidate mirnas for bladder
cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song T, Xia W, Shao N, Zhang X, Wang C, Wu
Y, Dong J, Cai W and Li H: Differential miRNA expression profiles
in bladder urothelial carcinomas. Asian Pac J Cancer Prev.
11:905–911. 2010.PubMed/NCBI
|
|
31
|
Zhao F, Ge YZ, Zhou LH, Xu LW, Xu Z, Ping
WW, Wang M, Zhou CC, Wu R and Jia RP: Identification of hub miRNA
biomarkers for bladder cancer by weighted gene coexpression network
analysis. Onco Targets Ther. 10:5551–5559. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang C, Chen L, Yang Y, Zhang M and Wong
G: Identification of bladder cancer prognostic biomarkers using an
ageing gene-related competitive endogenous RNA network. Oncotarget.
8:111742–111753. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Armstrong DA, Green BB, Seigne JD, Schned
AR and Marsit CJ: MicroRNA molecular profiling from matched tumor
and bio-fluids in bladder cancer. Mol Cancer. 14:1942015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y,
Zhang Y, Li X, Fan Y, Chen J, et al: MicroRNAs with prognostic
significance in bladder cancer: A systematic review and
meta-analysis. Sci Rep. 7:56192017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Friedel R, Diederichs F and Lindena J:
Advances in clinical enzymology. Basel, S. Karger AG; Switzerland:
1979, pp. 70–105
|
|
36
|
Hauser S, Wulfken LM, Holdenrieder S,
Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E,
Walgenbach-Brunagel G, von Ruecker A, et al: Analysis of serum
microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as
potential biomarkers in renal cell carcinoma. Cancer Epidemiol.
36:391–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wulfken LM, Moritz R, Ohlmann C,
Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel
G, von Ruecker A, Muller SC, et al: MicroRNAs in renal cell
carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS
One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fendler A, Stephan C, Yousef GM,
Kristiansen G and Jung K: The translational potential of microRNAs
as biofluid markers of urological tumours. Nat Rev Urol.
13:734–752. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
White MC, Holman DM, Boehm JE, Peipins LA,
Grossman M and Henley SJ: Age and cancer risk: A potentially
modifiable relationship. Am J Prev Med 46 (3 Suppl 1). S7–S15.
2014. View Article : Google Scholar
|
|
40
|
Miah S, Dudziec E, Drayton RM, Zlotta AR,
Morgan SL, Rosario DJ, Hamdy FC and Catto JW: An evaluation of
urinary microRNA reveals a high sensitivity for bladder cancer. Br
J Cancer. 107:123–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang X, Du L, Wang L, Li J, Liu Y, Zheng
G, Qu A, Zhang X, Pan H, Yang Y and Wang C: Serum microRNA
expression signatures identified from genome-wide microRNA
profiling serve as novel noninvasive biomarkers for diagnosis and
recurrence of bladder cancer. Int J Cancer. 136:854–862. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Binderup HG, Madsen JS, Heegaard NHH,
Houlind K, Andersen RF and Brasen CL: Quantification of microRNA
levels in plasma-Impact of preanalytical and analytical conditions.
PLoS One. 13:e02010692018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanaan Z, Roberts H, Eichenberger MR,
Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and
Galandiuk S: A plasma microRNA panel for detection of colorectal
adenomas: A step toward more precise screening for colorectal
cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Y, Chen J, Liu Y, Li S and Huang P:
Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for
hepatocellular carcinoma. Med Sci Monit. 21:1864–1871. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fogli S, Polini B, Carpi S, Pardini B,
Naccarati A, Dubbini N, Lanza M, Breschi MC, Romanini A and Nieri
P: Identification of plasma microRNAs as new potential biomarkers
with high diagnostic power in human cutaneous melanoma. Tumour
Biol. 39:10104283177016462017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang F, Zu Y, Zhu S, Yang Y, Huang W, Xie
H and Li G: Long noncoding RNA MAGI2-AS3 regulates CCDC19
expression by sponging miR-15b-5p and suppresses bladder cancer
progression. Biochem Biophys Res Commun. 507:231–235. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao C, Li Y, Chen G, Wang F, Shen Z and
Zhou R: Overexpression of miR-15b-5p promotes gastric cancer
metastasis by regulating PAQR3. Oncol Rep. 38:352–358. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Summerer I, Niyazi M, Unger K, Pitea A,
Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger
H: Changes in circulating microRNAs after radiochemotherapy in head
and neck cancer patients. Radiat Oncol. 8:2962013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu M, Luo Y, Cong Z, Mu Y, Qiu Y and Zhong
M: MicroRNA-590-5p inhibits intestinal inflammation by targeting
YAP. J Crohns Colitis. 12:993–1004. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dong L, Lin F, Wu W, Liu Y and Huang W:
Verteporfin inhibits YAP-induced bladder cancer cell growth and
invasion via Hippo signaling pathway. Int J Med Sci. 15:645–652.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ,
Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al:
Overexpression of YAP 1 contributes to progressive features and
poor prognosis of human urothelial carcinoma of the bladder. BMC
Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
van Kessel KE, Van Neste L, Lurkin I,
Zwarthoff EC and Van Criekinge W: Evaluation of an epigenetic
profile for the detection of bladder cancer in patients with
hematuria. J Urol. 195:601–607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang J, Zhou Y, Huang T, Wu F, Pan Y,
Dong Y, Wang Y, Chan AK, Liu L, Kwan JS, et al: FGF18, a prominent
player in FGF signaling, promotes gastric tumorigenesis through
autocrine manner and is negatively regulated by miR-590-5p.
Oncogene. 38:33–46. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Marzi MJ, Ghini F, Cerruti B, de Pretis S,
Bonetti P, Giacomelli C, Gorski MM, Kress T, Pelizzola M, Muller H,
et al: Degradation dynamics of microRNAs revealed by a novel
pulse-chase approach. Genome Res. 26:554–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gantier MP, McCoy CE, Rusinova I, Saulep
D, Wang D, Xu D, Irving AT, Behlke MA, Hertzog PJ, Mackay F and
Williams BR: Analysis of microRNA turnover in mammalian cells
following Dicer1 ablation. Nucleic Acids Res. 39:5692–5703. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo Y, Liu J, Elfenbein SJ, Ma Y, Zhong M,
Qiu C, Ding Y and Lu J: Characterization of the mammalian miRNA
turnover landscape. Nucleic Acids Res. 43:2326–2341. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Juracek J, Peltanova B, Dolezel J, Fedorko
M, Pacik D, Radova L, Vesela P, Svoboda M, Slaby O and Stanik M:
Genome-wide identification of urinary cell-free microRNAs for
non-invasive detection of bladder cancer. J Cell Mol Med.
22:2033–2038. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang X, Zhang Y, Liu X, Fang A, Wang J,
Yang Y, Wang L, Du L and Wang C: Direct quantitative detection for
cell-free miR-155 in urine: A potential role in diagnosis and
prognosis for non-muscle invasive bladder cancer. Oncotarget.
7:3255–3266. 2016.PubMed/NCBI
|
|
59
|
Du L, Jiang X, Duan W, Wang R, Wang L,
Zheng G, Yan K, Wang L, Li J, Zhang X, et al: Cell-free microRNA
expression signatures in urine serve as novel noninvasive
biomarkers for diagnosis and recurrence prediction of bladder
cancer. Oncotarget. 8:40832–40842. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tsujiura M, Ichikawa D, Komatsu S,
Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi
K, Fujiwara H, et al: Circulating microRNAs in plasma of patients
with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Le HB, Zhu WY, Chen DD, He JY, Huang YY,
Liu XG and Zhang YK: Evaluation of dynamic change of serum miR-21
and miR-24 in pre- and post-operative lung carcinoma patients. Med
Oncol. 29:3190–3197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Heneghan HM, Miller N, Lowery AJ, Sweeney
KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Aushev VN, Zborovskaya IB, Laktionov KK,
Girard N, Cros MP, Herceg Z and Krutovskikh V: Comparisons of
microRNA patterns in plasma before and after tumor removal reveal
new biomarkers of lung squamous cell carcinoma. PLoS One.
8:e786492013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Leidinger P, Keller A, Backes C, Huwer H
and Meese E: MicroRNA expression changes after lung cancer
resection: A follow-up study. RNA Biol. 9:900–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Leidinger P, Galata V, Backes C, Stähler
C, Rheinheimer S, Huwer H, Meese E and Keller A: Longitudinal study
on circulating miRNAs in patients after lung cancer resection.
Oncotarget. 6:16674–16685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Egidi MG, Cochetti G, Serva MR, Guelfi G,
Zampini D, Mechelli L and Mearini E: Circulating microRNAs and
kallikreins before and after radical prostatectomy: Are they really
prostate cancer markers? Biomed Res Int. 2013:2417802013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Keller A, Rounge T, Backes C, Ludwig N,
Gislefoss R, Leidinger P, Langseth H and Meese E: Sources to
variability in circulating human miRNA signatures. RNA Biol.
14:1791–1798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Aarsand AK, Roraas T, Fernandez-Calle P,
Ricos C, Diaz-Garzon J, Jonker N, Perich C, Gonzalez-Lao E,
Carobene A, Minchinela J, et al: The biological variation data
critical appraisal checklist: A standard for evaluating studies on
biological variation. Clin Chem. 64:501–514. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Burke HB: Increasing the power of
surrogate endpoint biomarkers: The aggregation of predictive
factors. J Cell Biochem. (Suppl 19):S278–S282. 1994.
|
